New treatment modalities in gastrointestinal malignancies: broadening the therapeutic horizon
Rapid advances in molecular targeting, immunotherapy optimisation and novel drug classes are reshaping gastrointestinal oncology
From bottleneck to breakthrough: rethinking clinical data collection in the age of AI
Every day, clinicians generate thousands of reports containing critical data that will never be analysed. Not because it lacks value — but because extracting it remains a bottleneck.
ctDNA is unlocking new clinical opportunities for liquid biopsy
Testing standardisation and optimal integration for routine clinical use remain challenging
Early-phase studies point to efficacy of a nectin-4-targeting antibody-drug conjugate in cervical cancer
In advanced or metastatic disease, bulumtatug fuvedotin shows promising efficacy and manageable safety
The antibody–drug conjugate era in gynaecological cancers
Recent approvals are driving a shift toward biomarker-informed treatment strategies, rational combinations and personalised sequencing
Targeting the CD47-SIRPα axis continues to show promise in solid tumours
In early-phase studies, two novel agents showed low propensity to induce heamatological toxicities in heavily pre-treated solid tumours
First-line dual targeting combination shows encouraging, durable responses in triple-negative breast cancer
A manageable safety profile was also reported for pumitamig plus the antibody-drug conjugate DB-1305/BNT325 in an early-phase study
Multimodal AI biomarkers: from biology to patient stratification
Artificial intelligence is enabling a new class of biomarkers by integrating histology, molecular data, imaging, and clinical records to generate scalable, biologically grounded insights for precision oncology.
Sustained quality-of-life benefits reported with first-line antibody-drug conjugate in triple negative breast cancer
Patient-reported outcomes show that datopotamab deruxtecan also improved patient functioning and symptom control compared to chemotherapy
Piccart: “Academic research is losing ground very rapidly”
At a senior stage of her career in oncology, Prof. Martine Piccart remains deeply committed in supporting young oncologists in cancer research